For research use only. Not for therapeutic Use.
Carisbamate（Cat No.:R013510）is an investigational anticonvulsant compound being developed for the treatment of epilepsy and other neurological disorders. It works by modulating neurotransmitter activity in the brain, specifically targeting ion channels and receptors involved in seizure generation and propagation. Carisbamate has demonstrated efficacy in reducing seizure frequency and severity in clinical trials. It is thought to act through a combination of mechanisms, including enhancing GABAergic inhibition and inhibiting glutamatergic excitation. Ongoing research aims to assess its long-term safety, effectiveness, and potential use as a treatment for refractory epilepsy and other neurological conditions.
| CAS Number | 194085-75-1 |
| Synonyms | [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate |
| Molecular Formula | C9H10ClNO3 |
| Purity | ≥95% |
| IUPAC Name | [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate |
| InChI | InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1 |
| InChIKey | OLBWFRRUHYQABZ-MRVPVSSYSA-N |
| SMILES | C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl |
